The Residential Real Estate Post-Crash Index-Moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Residential Real Estate Post-Crash Index-Moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Smiling Bob	4/27/2023 9:07:50 AM
	of 119358

Because keeping your mouth shut just isn't possible ----- Eli Lilly's Tirzepatide Achieved Up To 15.7% Weight Loss In Adults With Obesity Or Overweight And Type 2 Diabetes In Late-stage Trial -- MarketWatch 6:26 am ET April 27, 2023 (MarketWatch) Print Eli Lilly & Co. (LLY) said Thursday its tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in a late-stage trial. Participants in the phase 3 trial called Surmount-2 lost up to 34.4 pounds, the company said in a statement.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next